Abstract
We report on three type 2 diabetic patients whose daily basal insulin dose requirements were substantially reduced after switching from insulin detemir to insulin glargine. Meta-analysis of three randomised trials of basal insulin initiation confirmed this increased insulin detemir dose requirement in type 2 patients. Potential explanations are discussed.
MeSH terms
-
Adult
-
Blood Glucose / drug effects
-
Blood Glucose / metabolism
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Dose-Response Relationship, Drug
-
Female
-
Glycated Hemoglobin / metabolism
-
Humans
-
Hypoglycemic Agents / therapeutic use*
-
Insulin / analogs & derivatives*
-
Insulin / therapeutic use
-
Insulin Detemir
-
Insulin Glargine
-
Insulin, Long-Acting
-
Male
-
Meta-Analysis as Topic
-
Middle Aged
-
Randomized Controlled Trials as Topic
-
Weight Gain
Substances
-
Blood Glucose
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Insulin
-
Insulin, Long-Acting
-
Insulin Glargine
-
Insulin Detemir